

US FDA approves Axiostat first ever medical device that stops uncontrolled bleeding instantly [510(K) FDA clearance]



Introducing
100% Chitosan
Haemostatic Dressing

axiostat[®]
stops bleeding, instantly



Uncontrolled Bleeding Burden

What is Uncontrolled Bleeding ?

- A profuse discharge of **blood**, as from a ruptured **blood** vessel; **bleeding**. the loss of assets, especially in large amounts. any widespread or **uncontrolled** loss or diffusion.
- **Symptoms include but not limited to:**
Easy bruising, Bleeding gums, Heavy **bleeding** from small cuts or dental work, Excessive bleeding following surgery.

Battlefield
Proven
Technology

Extensively used by
Defense forces Globally



Stop Bleeding,
Instantly

with **axiostat**


Reinventing
Woundcare



Facts and Figures

Worldwide, an estimated 5 million people died as a result of injury in 2000, with a mortality rate of 83 per 100,000 of the population. Injury represented 9% of worldwide deaths and 12% of the burden of disease . More than 90% of injury-related fatalities occur in low- and middle-income nations. The highest mortality rates from injury occur in the less wealthy nations in Eastern Europe, with the lowest rates in North America, Western Europe, China, Japan, and Australia . Globally, road traffic injuries result in 1.2 million deaths per year, with an additional 20–50 million injuries. They rank as the 11th leading cause of death overall, accounting for 2.1% of all deaths worldwide and 25% of injury-related deaths . Violence is a large contributor to injury-related fatality as well, with 1.6 million deaths worldwide in 2000, representing 16% of mortality from injury . It is by far the leading cause of death among those aged 15–44 years and is much more prevalent in low- to middle-income countries . Self-inflicted violence represents 16% of injury-related mortality worldwide, with falls and burns accounting for 6% and 5%, respectively

Top 10 causes of death globally 2015



About Axiostat

About the MEDICAL DEVICE

- Talking about the product, Leo Mavelly, founder and CEO of Bengaluru-headquartered Axio Biosolutions, says, while the company was set up about a decade ago, it went commercial only in 2014. It got the approval from the US drug regulator in February this year.
- The company has already raised a total of over Rs 60 crore from Ratan Tata's RNT Capital (early this year) and earlier from Accel Partners and IDG Ventures India. It wants to focus on India and other emerging markets, while at some stage, perhaps sometime in 2019, it may also look at a foray into the US market. It already has an office in Boston and is scouting for a partner in the US - could be a group purchasing organization or a large distributor that works with the public health system in the US.


Axio Biosolutions secures \$7.4m funding from Ratan Tata

PHARMA STATE

Brief on Axiostat

- Axiostat is a quick & effective intervention can stop most of these preventable deaths. It has been proven to reduce the time taken to stop severe external bleeding in under 5 minutes.

Advantages: Sterile [ready to use], Easy **painless removal], Effective in patients on blood thinner, Can be cut, folded, stuffed into deep wounds.**



About AXIOSTAT


Product information

- **Composition:** Chitosan - 100% (from shellfish)
- **Shelf Life:** 3 Years
- **Use:** Single-use
- **Side Effects:** No side effects
- **Indications For Use:** Axiostat Chitosan Hemostatic Dressing is indicated to control bleeding of lacerations, minor cuts and abrasions.
- The patch when applied on a wound, reacts with blood and within a minute of application forms a clot and becomes an extremely sticky adhesive.



Mechanism of action

- Charge-based mucoadhesion and blood-cell aggregation.



Stops Severe External Bleeding
Established Proven Technology

100% Chitosan Dressing
Easy to use... painless to remove

Cost Effective
Innovation that saves lives

Sterile Single-Use
3 Years Shelf Life

Control bleeding during **radial & femoral** vascular procedures

Effective on patients on **blood thinners**

Competitive Landscape

Current Treatment options

1. **APTT** [Activated Partial Thromboplastin Time]
2. **CT** [Computed Tomography]
3. **Hb** [Haemoglobin]
4. **PCC** [Prothrombin Complex Concentrate]
5. **PT** [Prothrombin Time]
6. **Anti- fibrinolytic agents**
7. **Desmopressin**
8. **Anti- platelet agents**



Competitive landscape for Axiostat

 iTraumaCare™

 Care

Z-MEDICA

 CHRISTIE+

 REVMED^x

 MEDICA®



PHARMA STATE

www.pharmastate.com

For Any Feedback or Suggestions mail at: info@pharmastate.com



PHARMA STATE



GET IT ON
Google Play



Download on the
App Store

Disclaimer

The information in this presentation was compiled from sources believed to be reliable for informational purposes only. We do not guarantee the accuracy of this information or any results and further assume no liability in connection with this publication, including any information, methods or safety suggestions contained herein. Moreover, this presentation cannot be assumed to contain every acceptable safety and compliance procedure. PharmaState or its any affiliate has no liability to the content presented in the slide deck. Also the users are advised to confirm the accuracy of information from the valid & reliable sites & are advised not to take the information of this slide as final. PharmaState is neither promoting nor endorsing any product with this information. This information is for scientific update only. User discretion is advised for comprehension of provided information.

